Published in final edited form as:

Bioorg Med Chem Lett. 2013 December 15; 23(24): 6920–6922. doi:10.1016/j.bmcl.2013.09.038.

Chlorophenylpiperazine analogues as high affinity dopamine transporter ligands

William C. Motel^{#a}, Jason R. Healy^{#b}, Eddy Viard^b, Buddy Pouw^c, Kelly Martin, Rae R. Matsumoto^{b,c}, and Andrew Coop^{a,*}

^aDepartment of Pharmaceutical Sciences, University of Maryland, School of Pharmacy, 20 North Pine Street, Baltimore, MD, 21201, USA

^bDepartment of Basic Pharmaceutical Sciences, West Virginia University, School of Pharmacy, One Medical Center Drive, Morgantown, WV, 26506, USA

^cDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, College of Pharmacy, Oklahoma City, OK, 73190, USA

These authors contributed equally to this work.

Abstract

Selective σ_2 ligands continue to be an active target for medications to attenuate the effects of psychostimulants. In the course of our studies to determine the optimal substituents in the σ_2 -selective phenyl piperazines analogues with reduced activity at other neurotransmitter systems, we discovered that 1-(3-chlorophenyl)-4-phenethylpiperazine actually had preferentially increased affinity for dopamine transporters (DAT), yielding a highly selective DAT ligand.

Keywords

sigma receptor; dopamine transporter; structure-activity relationships; neurotransmitter; cocaine; methamphetamine

Drugs that have the capability to suppress the stimulant and toxic activities of psychomotor stimulants are urgently required, yet little success has been achieved.¹⁻⁶ Our studies have shown that selective sigma (σ) receptor antagonists can attenuate stimulant and neurotoxic effects of cocaine and methamphetamine in rodents.⁷⁻¹¹ However, elucidation of the specific receptor subtypes (σ_1 and σ_2) involved are hampered by the paucity of σ_2 -selective ligands.¹²

In earlier studies, simple piperazine analogues demonstrated anti-psychostimulant activity with affinity for both σ receptor subtypes.¹³⁻¹⁶ We expanded the library of piperazine analogues through the exploration of an electron withdrawing pyridyl ring linked to the piperazine, yielding *N*-(2-pyridyl)piperazine analogues, which favors the σ_2 receptor subtype over the σ_1 receptor subtype.^{17, 18} To further explore σ_2 -selective piperazine

© 2013 Elsevier Ltd. All rights reserved.

*CORRESPONDING AUTHOR University of Maryland, Department of Pharmaceutical Sciences, School of Pharmacy, 20 Penn St., Baltimore, Maryland, 21201, Tel: 1-410-706-2029; Fax: 1-410-706-4012; acoop@rx.umaryland.edu. .

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

analogues, we introduced electron withdrawing chloro-substituents into the σ_2 -selective 1-(3-phenylpropyl)-4-(2-pyridyl)piperazine (**UMB38**) scaffold to create a series of ligands that were pharmacologically evaluated at both the σ_1 and σ_2 receptor subtypes in addition to commonly tested neurotransmitter receptors and transporters that have historically been of concern for off-target interactions of σ ligands.

The analogues (**2-7**, Fig. 1) were prepared by the reaction of the appropriate phenyl piperazine and the appropriate brominated phenyl alkane in DMF in the presence of NaHCO_3 at room temperature for 24 h. The product was extracted from water into diethyl ether and concentrated. Yields of pure free bases were observed between 87 and 97%. After removal of the solvent, all amines were converted into water-soluble oxalic acid salts. All free bases displayed NMR and mass spectral data consistent with the assigned structures, and combustion analysis of all salts were $\pm 0.4\%$ of the theoretical calculation (Atlantic Microlabs, Norcross, GA, USA). A more detailed chemical description can be found in the supplementary data section. The synthesized ligands were evaluated using competition binding assays as previously described.^{9, 16, 19}

This series of piperazine analogues showed high-to-moderate affinity for both σ_1 and σ_2 receptor subtypes (Table 1). σ Binding affinities have previously been published for **3**, **6** and **7**; however, said binding affinities were obtained using [^3H]di-*o*-tolylguanidine (DTG) without the inclusion of (+)-pentazocine, conditions that do not differentiate affinities between the σ_1 and σ_2 receptor subtypes.²⁰ While the primary objective of this research was to identify electron withdrawing chloro-substituents that optimize σ_2 -selectivity, unfortunately, all selectivity was lost upon removal of the 2-pyridyl functional group. As such, the 2-,3- and 4-chloro moieties were unable to sustain or improve σ_2 -selectivity.

Of particular interest was the dopamine transporter (DAT) binding affinities for the chloro-substituted phenylethyl ligands. **2**, **3** and **4** displayed high affinity for DAT, whereby **3** displayed the greatest selectivity for DAT (>160-fold) at all sites tested compared to other ligands herein. Psychostimulant use, including both cocaine and methamphetamine, has been shown to affect DAT function.²¹ Previous studies have identified phenyl-substituted piperazine derivatives classified as DAT inhibitors, including 1-(2-(bis(4-fluorophenyl)-methoxy)-ethyl)-4-(3-phenyl-propyl)piperazine (**GBR12909**),²² that have been extensively studied as anti-cocaine therapeutics; however, problematic side-effect liabilities associated with **GBR12909** have halted future clinical studies.²³

With respect to our initial research intent as well as unexpected findings, ligands depicting dual interactions with DAT and σ receptors can potentially attenuate the behavioral effects of psychostimulants.^{24, 25} Simultaneous DAT/ σ receptor inhibition can effectively reduce cocaine self-administration,²⁶ an effect not seen with σ receptor antagonists alone.^{27, 28} Furthermore, structure activity relationships (SAR) of dual DAT/ σ_1 ligands have been investigated with the intent of curbing psychostimulant abuse,^{29, 30} with the σ_1 receptor subtype more definitely established as a potential therapeutic target for psychostimulant abuse to that of the σ_2 receptor subtype.^{31, 32} Ligands herein that are σ_1 -selective (**5** and **7**), DAT-selective (**3**) or demonstrate dual σ_1 /DAT activity (**2**) offer potential for future anti-psychostimulant medication development.

Although not the result expected, the SAR herein uncovered one of the highest affinity and most selective ligands for DAT (**3**). This compound has the potential to increase our understanding of DAT, while informing that such substituents are not appropriate for σ_2 selective ligands.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was supported by the National Institutes of Health (DA011979, DA013978). Mr. Jason Healy was supported by a diversity supplement from the National Institutes of Health (DA013583).

REFERENCES

1. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, Lecomte T. J. Psychiatry Neurosci. 2006; 31:301. [PubMed: 16951733]
2. Cruickshank CC, Dyer KR. Addiction. 2009; 104:1085. [PubMed: 19426289]
3. Grabowski J, Shearer J, Merrill J, Negus SS. Addict. Behav. 2004; 29:1439. [PubMed: 15345275]
4. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, Blecha L, Lowenstein W, Martinot JL, Reynaud M, Lepine JP. Int. J. Neuropsychopharmacol. 2008; 11:425. [PubMed: 17927843]
5. Preti A. Addict. Biol. 2007; 12:133. [PubMed: 17508985]
6. Sofuoglu M, Kosten TR. Expert Opin. Emerg. Drugs. 2006; 11:91. [PubMed: 16503828]
7. Kaushal N, Robson MJ, Vinnakota H, Narayanan S, Avery BA, McCurdy CR, Matsumoto RR. AAPS J. 2011; 13:336. [PubMed: 21494909]
8. Kaushal N, Seminerio MJ, Robson MJ, McCurdy CR, Matsumoto RR. Eur. Neuropsychopharmacol. 2013; 23:960. [PubMed: 22921523]
9. Matsumoto RR, Shaikh J, Wilson LL, Vedam S, Coop A. Eur. Neuropsychopharmacol. 2008; 18:871. [PubMed: 18755577]
10. Robson MJ, Turner RC, Naser ZJ, McCurdy CR, Huber JD, Matsumoto RR. Exp. Neurol. 2013; 247C:134. [PubMed: 23631864]
11. Seminerio MJ, Hansen R, Kaushal N, Zhang HT, McCurdy CR, Matsumoto RR. Int. J. Neuropsychopharmacol. 2013; 16:1033. [PubMed: 22932447]
12. Abate C, Mosier PD, Berardi F, Glennon RA. Cent. Nerv. Syst. Agents Med. Chem. 2009; 9:246. [PubMed: 20021358]
13. Foster A, Wu H, Chen W, Williams W, Bowen WD, Matsumoto RR, Coop A. Bioorg. Med. Chem. Lett. 2003; 13:749. [PubMed: 12639573]
14. Kaushal N, Seminerio MJ, Shaikh J, Medina MA, Mesangeau C, Wilson LL, McCurdy CR, Matsumoto RR. Neuropharmacology. 2011; 61:992. [PubMed: 21762711]
15. Matsumoto RR, Pouw B, Mack AL, Daniels A, Coop A. Pharmacol. Biochem. Behav. 2007; 86:86. [PubMed: 17241657]
16. Xu YT, Kaushal N, Shaikh J, Wilson LL, Mesangeau C, McCurdy CR, Matsumoto RR. J. Pharmacol. Exp. Ther. 2010; 333:491. [PubMed: 20100904]
17. Maeda DY, Williams W, Kim WE, Thatcher LN, Bowen WD, Coop A. Bioorg. Med. Chem. Lett. 2002; 12:497. [PubMed: 11814827]
18. Stavitskaya L, Seminerio MJ, Matthews-Tsourounis MM, Matsumoto RR, Coop A. Bioorg. Med. Chem. Lett. 2010; 20:2564. [PubMed: 20338757]
19. Stavitskaya L, Seminerio MJ, Healy JR, Noorbakhsh B, Matsumoto RR, Coop A. Bioorg. Med. Chem. 2013; 21:4923. [PubMed: 23896610]
20. Glennon RA, Yousif MY, Ismaiel AM, el-Ashmawy MB, Herndon JL, Fischer JB, Server AC, Howie KJ. J. Med. Chem. 1991; 34:3360. [PubMed: 1662725]
21. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, Newman AH, Javitch JA, Weinstein H, Gether U, Loland C. J. Nat. Neurosci. 2008; 11:780.
22. Andersen PH. Eur. J. Pharmacol. 1989; 166:493. [PubMed: 2530094]
23. Xi, Z-X. Addictions - From Pathophysiology to Treatment. Belin, D., editor. InTech; 2012.

24. Katz JL, Libby TA, Kopajtic T, Husbands SM, Newman AH. Eur. J. Pharmacol. 2003; 468:109. [PubMed: 12742518]
25. Newman AH, Kulkarni S. Med. Res. Rev. 2002; 22:429. [PubMed: 12210554]
26. Hiranita T, Soto PL, Kohut SJ, Kopajtic T, Cao J, Newman AH, Tanda G, Katz JL. J. Pharmacol. Exp. Ther. 2011; 339:662. [PubMed: 21859929]
27. Hiranita T, Soto PL, Tanda G, Katz JL. J. Pharmacol. Exp. Ther. 2010; 332:515. [PubMed: 19892920]
28. Martin-Fardon R, Maurice T, Aujla H, Bowen WD, Weiss F. Neuropsychopharmacology. 2007; 32:1967. [PubMed: 17268407]
29. Cao J, Kulkarni SS, Husbands SM, Bowen WD, Williams W, Kopajtic T, Katz JL, George C, Newman AH. J. Med. Chem. 2003; 46:2589. [PubMed: 12801223]
30. Cao J, Kopajtic T, Katz JL, Newman AH. Bioorg. Med. Chem. Lett. 2008; 18:5238. [PubMed: 18774292]
31. Narayanan S, Mesangeau C, Poupaert JH, McCurdy CR. Curr. Top. Med. Chem. 2011; 11:1128. [PubMed: 21050176]
32. Nguyen EC, McCracken KA, Liu Y, Pouw B, Matsumoto RR. Neuropharmacology. 2005; 49:638. [PubMed: 15939443]

Figure 1.
Template compound UMB38 and chloro-substituted analogues.

Table 1

Competition binding study results for σ receptors and dopamine transporters. Values are reported as $K_i \pm$ S.E.M. (nM). A value of >10,000 indicates less than 30% of the radioligand was displaced at the 10,000 nM ligand concentration. DAT = dopamine transporter; n.d. = not determined. σ_1/σ_2 and σ_1/DAT are selectivity ratios, respectively.

Compound	σ_1	σ_2	σ_1/σ_2	DAT	σ_1/DAT
UMB38	$82 \pm 0.2^*$	$4.9 \pm 0.8^*$	16.73	9148 ± 1008	0.0090
2	0.15 ± 0.01	56.32 ± 4.16	0.003	0.13 ± 0.01	1.15
3	6.47 ± 0.48	82.31 ± 6.77	0.079	0.04 ± 0.01	161.75
4	1.85 ± 0.20	33.30 ± 2.02	0.056	6 ± 0.33	0.31
5	0.56 ± 0.06	7.79 ± 0.52	0.072	482 ± 24	0.0012
6	4.93 ± 0.52	12.59 ± 1.17	0.39	>10,000	n.d.
7	0.12 ± 0.003	10.89 ± 0.97	0.011	2647 ± 158	0.000045

* Data from previously reported compound ref. 17.

Table 2

Competition binding study results for neurotransmitter receptors and transporters. Values are reported as $K_i \pm$ S.E.M. (nM). A value of >10,000 indicates less than 30% of the radioligand was displaced at the 10,000 nM ligand concentration. 5-HT₂ = serotonin receptor subfamily; D₂ = dopamine receptor subtype; SERT = serotonin transporter; NET = norepinephrine transporter; PCP/NMDA = phencyclidine/N-methyl-D-aspartate.

Compound	5-HT ₂	D ₂	SERT	NET	Opioid	PCP/NMDA
UMB38	1238 ± 61	940 ± 87	>10,000	>10,000	>10,000	>10,000
2	484 ± 6	67 ± 6	>10,000	790 ± 33	4830 ± 391	>10,000
3	53 ± 7	327 ± 23	802 ± 68	1107 ± 35	>10,000	>10,000
4	518 ± 52	834 ± 56	372 ± 13	>10,000	>10,000	>10,000
5	952 ± 98	77 ± 7	409 ± 29	>10,000	4600 ± 495	>10,000
6	498 ± 50	128 ± 9	488 ± 36	>10,000	>10,000	>10,000
7	391 ± 48	660 ± 19	1104 ± 92	>10,000	>10,000	>10,000